ProQR Therapeutics N.V. (PRQR) Form 6-K — Aug 13, 2026
ProQR Therapeutics reported a Q2 2026 net loss of €8.7 million (€0.08 per diluted share), improved from a €12.2 million loss (€0.12 per share) in the year-ago quarter, on revenue of €8.8 million versus €3.8 million a year earlier. R&D costs rose modestly to €12.7 million from €11.4 million. The headline news was the first clinical validation of the company's Axiomer RNA editing platform: AX-0810 produced dose-dependent NTCP target engagement in healthy volunteers, with up to an 8-fold increase in total serum bile acids at 6 mg/kg, an 8-week half-life, and no serious adverse events reported.
Key figures
- Eps
- -€0.08 per diluted share (Q2 2026, vs -€0.12 Q2 2025)
- Revenue
- €8.76 million (Q2 2026, vs €3.82 million Q2 2025)
- Net Income
- -€8.7 million net loss (Q2 2026, vs -€12.2 million Q2 2025)
- Total Assets
- €133.6 million
- Cash Position
- €117.1 million at June 30, 2026 (vs €92.4 million at December 31, 2025)
- Gross Proceeds
- $59.2 million (June 2026 registered direct offering plus Lilly private placement)
- Shares Offered
- 32,725,090 ordinary shares total (27,624,310 registered direct + 5,100,780 Lilly private placement)
- Shares Outstanding
- 143466309
- Cash runway
- through mid-2028
- Ax0810 half life
- 8 weeks
- Ga costs q2 2026
- €4.9 million (vs €4.8 million Q2 2025)
- H1 2026 net loss
- €22.1 million
- Rnd costs q2 2026
- €12.7 million (vs €11.4 million Q2 2025)
- Ax0811 initial data
- expected by year-end 2026, pending EMA CTA authorization
- Lilly private placement
- $9.2 million
- Ax0810 bile acid increase
- up to 8-fold at 6 mg/kg (vs 2-fold threshold)
- Registered direct offering
- $50.0 million
- Net cash used in operating q2 2026
- €12.3 million (vs €11.4 million Q2 2025)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.